BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22648851)

  • 1. [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
    Zhang T; Su LW; Zhu YF; Lang HJ; Zhang F; Zhou YA; Liang XH; Wang YJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 May; 15(5):512-6. PubMed ID: 22648851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
    Liu FX; Wang WH; Wang J; Li J; Gao PP
    Helicobacter; 2011 Feb; 16(1):66-77. PubMed ID: 21241415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].
    Miwa K; Oyama K; Fujimura T
    Nihon Rinsho; 2005 Aug; 63(8):1387-93. PubMed ID: 16101227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemoprevention of Barrett's esophagus by celecoxib in rats].
    Wang RH; Ou-Yang Q; Chen X; Li GD; Xiang JY
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):498-504. PubMed ID: 19830863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats.
    Oyama K; Fujimura T; Ninomiya I; Miyashita T; Kinami S; Fushida S; Ohta T; Koichi M
    Carcinogenesis; 2005 Mar; 26(3):565-70. PubMed ID: 15564290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
    Esquivias P; Morandeira A; Escartín A; Cebrián C; Santander S; Esteva F; García-González MA; Ortego J; Lanas A; Piazuelo E
    World J Gastroenterol; 2012 Sep; 18(35):4866-74. PubMed ID: 23002358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
    Buttar NS; Wang KK; Leontovich O; Westcott JY; Pacifico RJ; Anderson MA; Krishnadath KK; Lutzke LS; Burgart LJ
    Gastroenterology; 2002 Apr; 122(4):1101-12. PubMed ID: 11910360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
    Tang BD; Zeng ZR; Hu PJ
    Ai Zheng; 2006 Oct; 25(10):1205-9. PubMed ID: 17059761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
    Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
    Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide].
    Oyama K; Fujimura T; Ninomiya I; Miyashita T; Kinami S; Fushida S; Ohta T
    Nihon Shokakibyo Gakkai Zasshi; 2007 Aug; 104(8):1183-91. PubMed ID: 17675820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
    Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
    J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
    Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
    J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model.
    Esquivias P; Cebrián C; Morandeira A; Santander S; Ortego J; García-González MA; Lanas A; Piazuelo E
    Oncol Rep; 2014 Jun; 31(6):2785-91. PubMed ID: 24737143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
    Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
    J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention and Barrett's esophagus: decisions, decisions.
    Falk GW; Jankowski J
    Am J Gastroenterol; 2008 Oct; 103(10):2443-5. PubMed ID: 18775008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
    Hur C; Broughton DE; Ozanne E; Yachimski P; Nishioka NS; Gazelle GS
    Am J Gastroenterol; 2008 Oct; 103(10):2432-42. PubMed ID: 18775019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis.
    Vardar-Sengul S; Buduneli E; Turkoglu O; Buduneli N; Atilla G; Wahlgren J; Sorsa T; Baylas H
    J Periodontol; 2008 Oct; 79(10):1934-41. PubMed ID: 18834249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats.
    Vardar S; Buduneli E; Baylas H; Berdeli AH; Buduneli N; Atilla G
    J Periodontol; 2005 Jan; 76(1):99-106. PubMed ID: 15830643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy.
    Rocha FT; Lourenço LG; Jucá MJ; Costa V; Leal AT
    Acta Cir Bras; 2009; 24(3):189-94. PubMed ID: 19504000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
    Pawlik M; Pajdo R; Kwiecien S; Ptak-Belowska A; Sliwowski Z; Mazurkiewicz-Janik M; Konturek SJ; Pawlik WW; Brzozowski T
    J Physiol Pharmacol; 2011 Feb; 62(1):75-86. PubMed ID: 21451212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.